We came across a bullish thesis on Willdan Group, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on WLDN. Willdan Group, Inc.'s share was trading at $117.10 as of February 25th. WLDN’s trailing and forward P/E were 38.96 and 22.52 respectively according to Yahoo Finance. "People Didn't Like" Paychex (PAYX)'s Quarter everything possible/Shutterstock.com Willdan Group, Inc., together with its subsidiaries, provides professional, technical, and consulting services primari ...

We came across a bullish thesis on Willdan Group, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on WLDN. Willdan Group, Inc.'s share was trading at $117.10 as of February 25th. WLDN’s trailing and forward P/E were 38.96 and 22.52 respectively according to Yahoo Finance. "People Didn't Like" Paychex (PAYX)'s Quarter everything possible/Shutterstock.com Willdan Group, Inc., together with its subsidiaries, provides professional, technical, and consulting services primari ...

Core Viewpoint - The U.S.-Iran conflict is expected to lead to an increase in rates, while shares of companies like Frontline and DHT Holdings have already experienced a rally [1] Company and Industry Summary - Frontline's shares have shown significant gains amid the geopolitical tensions [1] - DHT Holdings has also seen a rise in its stock price, reflecting investor optimism in the shipping sector due to the conflict [1]

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

We came across a bullish thesis on Celldex Therapeutics, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on CLDX. Celldex Therapeutics, Inc.'s share was trading at $30.82 as of February 25th. test, cancer, researcher, research, dna, bio, clean, modern, chemistry, human, white, medical, sample, pipette, life, culture, laboratory, biotechnology, genetic, disease, science photo/Shutterstock.com Celldex Therapeutics Inc. (CLDX) is emerging as an attractive biotech pick for ...

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

We came across a bullish thesis on Rithm Capital Corp. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on RITM. Rithm Capital Corp.'s share was trading at $10.22 as of February 25th. RITM’s trailing and forward P/E were 8.59 and 5.08 respectively according to Yahoo Finance. BlackRock, Inc. (BLK): People Sent Me Emails Saying I Don't Know Anything, Says Jim Cramer Rithm Capital Corp. (RITM) has evolved into a diversified asset manager by combining mortgage servicing with alter ...

We came across a bullish thesis on MannKind Corporation on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on MNKD. MannKind Corporation's share was trading at $3.5000 as of February 25th. MNKD’s trailing and forward P/E were 49.91 and 34.36, respectively according to Yahoo Finance. Top 12 Anesthesiology Residency Programs in 2018 Cherries/Shutterstock.com MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic d ...

We came across a bullish thesis on MannKind Corporation on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on MNKD. MannKind Corporation’s share was trading at $3.5000 as of February 25th. MNKD’s trailing and forward P/E were 49.91 and 34.36, respectively according to Yahoo Finance. MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. MNKD is emerging as a compelling growth story, driven by its lead ...

Core Insights - Cava Group's stock has increased by approximately 45% year to date, although it remains down about 15% over the past year, following a positive fourth-quarter earnings report and guidance [1] Financial Performance - Cava's Q4 revenue rose by 21% year over year to $272.8 million, with the company opening 24 new restaurants, bringing the total to 439 locations, a nearly 20% increase compared to the previous year [3] - Adjusted EBITDA increased by 3% year over year to $25.8 million, with operating cash flow for the year at $184.8 million and free cash flow at $26.1 million [6] Sales Growth and Forecast - The company forecasts comparable-restaurant sales growth of 3% to 5% for 2026, a significant improvement compared to the 0.5% increase reported in Q4 of 2025 [3] - Cava's restaurant-level margins (RLMs) were 21.4% in Q4, down from 22.4% a year ago, with an expected RLM of 23.7% to 24.2% for 2026 [5] Expansion Plans - Cava plans to open between 74 and 76 new locations in fiscal 2026, continuing its expansion into new Midwest markets, including Cincinnati, St. Louis, Columbus, and Minneapolis [4] - The company's long-term goal is to reach at least 1,000 restaurants by 2032 [4] Business Model and Strategy - Cava has strong average unit volumes (AUVs) of nearly $3 million and employs a strategy similar to Chipotle, focusing on minimal ingredients that can be used in various combinations [8] - With fewer than 450 locations, Cava is positioned as one of the best expansion stories in the restaurant industry [8]